Floatz logo

Lanreotide

Lymphocele

University Hospital, Limogesprotein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Lymphocele cohort.

Asset / SponsorPhaseRating
Indocyanine Green
Kaiser Permanente
Phase 4BB
HEPARIN
Johns Hopkins University
Phase 4B
Fibrin Sealant Vh S/D
Baxter Healthcare Corporation
Phase 3NR

Same molecule, other indications

Lanreotide is also rated in:

non-functional pancreatic neuroendocrine tumorDormant
BB
Indicative ·
64 / 100
View asset →
malignant endocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
Rectal CarcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →